Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TBio-6517||RIVAL-01||TBio-6517 is an engineered vaccinia virus that expresses the Flt3 ligand, an antibody targeting CTLA4, and the cytokine IL-12, which may lead to immune activation and increased anti-tumor immune response, and decreased tumor cell proliferation (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04301011||Phase Ib/II||TBio-6517 Pembrolizumab + TBio-6517||Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR)||Recruiting||USA | CAN||1|